Cypherpunk Technologies Inc. (CYPH)
CYPH Stock Price Chart
Explore Cypherpunk Technologies Inc. interactive price chart. Choose custom timeframes to analyze CYPH price movements and trends.
CYPH Company Profile
Discover essential business fundamentals and corporate details for Cypherpunk Technologies Inc. (CYPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jan 2017
Employees
52.00
Website
https://www.leaptx.comCEO
Douglas E. Onsi
Description
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
CYPH Financial Timeline
Browse a chronological timeline of Cypherpunk Technologies Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.03.
Earnings released on 14 May 2026
EPS came in at -$0.46 falling short of the estimated -$0.04 by -1.03k%.
Earnings released on 16 Mar 2026
EPS came in at -$0.23 falling short of the estimated -$0.07 by -246.39%.
Earnings released on 12 Nov 2025
EPS came in at -$0.08 surpassing the estimated -$0.24 by +66.67%, while revenue for the quarter reached $209.00k .
Earnings released on 14 Aug 2025
EPS came in at -$0.40 falling short of the estimated -$0.29 by -37.93%.
Earnings released on 13 May 2025
EPS came in at -$0.37 surpassing the estimated -$0.38 by +2.63%.
Earnings released on 26 Mar 2025
EPS came in at -$0.37 surpassing the estimated -$0.39 by +5.13%.
Earnings released on 13 Nov 2024
EPS came in at -$0.44 surpassing the estimated -$0.46 by +4.35%.
Earnings released on 12 Aug 2024
EPS came in at -$0.52 falling short of the estimated -$0.42 by -23.81%.
Earnings released on 13 May 2024
EPS came in at -$0.51 surpassing the estimated -$0.57 by +10.53%.
Earnings released on 18 Mar 2024
EPS came in at -$0.46 surpassing the estimated -$0.56 by +17.86%, while revenue for the quarter reached $634.00k .
Earnings released on 13 Nov 2023
EPS came in at -$0.51 falling short of the estimated -$0.48 by -6.25%.
Earnings released on 14 Aug 2023
EPS came in at -$0.91 surpassing the estimated -$0.98 by +7.14%.
Stock split effective on 21 Jun 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2023
EPS came in at -$3.20 falling short of the estimated -$0.90 by -255.56%.
Earnings released on 24 Mar 2023
EPS came in at -$1.10 falling short of the estimated -$0.90 by -22.22%.
Earnings released on 14 Nov 2022
EPS came in at -$1.30 falling short of the estimated -$1.10 by -18.18%.
Earnings released on 12 Aug 2022
EPS came in at -$1.50 falling short of the estimated -$1.00 by -50.00%.
Earnings released on 13 May 2022
EPS came in at -$0.90 surpassing the estimated -$1.10 by +18.18%.
Earnings released on 11 Mar 2022
EPS came in at -$1.00 surpassing the estimated -$1.10 by +9.09%, while revenue for the quarter reached $375.00k , missing expectations by -2.85%.
Earnings released on 12 Nov 2021
EPS came in at -$1.40 falling short of the estimated -$1.10 by -27.27%, while revenue for the quarter reached $375.00k , beating expectations by +20.97%.
Earnings released on 13 Aug 2021
EPS came in at -$1.20 surpassing the estimated -$1.30 by +7.69%, while revenue for the quarter reached $375.00k , meeting expectations.
CYPH Stock Performance
Access detailed CYPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
